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A glucose-responsive “closed-loop” insulin delivery system mimick-
ing the function of pancreatic cells has tremendous potential to
improve quality of life and health in diabetics. Here, we report a
novel glucose-responsive insulin delivery device using a painless
microneedle-array patch (“smart insulin patch”) containing glucose-
responsive vesicles (GRVs; with an average diameter of 118 nm),
which are loaded with insulin and glucose oxidase (GOx) enzyme.
The GRVs are self-assembled from hypoxia-sensitive hyaluronic acid
(HS-HA) conjugated with 2-nitroimidazole (NI), a hydrophobic com-
ponent that can be converted to hydrophilic 2-aminoimidazoles
through bioreduction under hypoxic conditions. The local hypoxic
microenvironment caused by the enzymatic oxidation of glucose
in the hyperglycemic state promotes the reduction of HS-HA, which
rapidly triggers the dissociation of vesicles and subsequent release
of insulin. The smart insulin patch effectively regulated the blood
glucose in a mouse model of chemically induced type 1 diabetes. The
described work is the first demonstration, to our knowledge, of a
synthetic glucose-responsive device using a hypoxia trigger for reg-
ulation of insulin release. The faster responsiveness of this approach
holds promise in avoiding hyperglycemia and hypoglycemia if trans-
lated for human therapy.
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Diabetes mellitus is a group of metabolic diseases character-ized by failure of blood glucose level regulation mechanisms
(1, 2). As of 2014, 387 million people suffered from diabetes
worldwide, and the number is estimated to be 592 million by
2035 (3, 4). The traditional care for people with diabetes often
requires monitoring of blood glucose and insulin injections to
maintain normoglycemia (5). However, such self-administration
is associated with pain and often inadequate glucose control (6–
8). Poor glucose control accounts for a high risk for complica-
tions of diabetes, including limb amputation, blindness, and
kidney failure. Additionally, hypoglycemia can result in behav-
ioral and cognitive disturbance, seizure, loss of consciousness,
coma, brain damage, or death (9).
An artificial pancreas-like, closed-loop, glucose-responsive in-
sulin delivery system that is able to “secrete” insulin in response to
elevated blood glucose would provide a desirable way of regulating
glycemia with minimal patient effort and potential improvements in
glycemia and quality of life (6, 7, 10). Current closed-loop systems
combine a glucose-monitoring module and a sensor-triggered in-
sulin releasing module (6, 7). There are closed-loop electronic/
mechanical devices that use a continuous glucose-monitoring sen-
sor calibrated by the patient and an external insulin infusion pump
(8). However, challenges associated with such devices, such as
guaranteeing accurate signal feedback and preventing biofouling,
still persist. A chemical approach using an insulin-loaded matrix
with glucose-sensing elements and a relevant actuator could avoid
those limitations and may prove more effective for closed-loop
insulin release. The matrix can undergo structural transformations
(i.e., shrink, swell, dissociate) regulated by glucose concentration
changes, leading to glucose-stimulated insulin release (11–14). The
typical glucose-sensing moieties include phenylboronic acid (PBA),
glucose-binding protein (GBP), and glucose oxidase (GOx) (12–
20). Despite these available sensing chemistries, the majority of
existing synthetic closed-loop systems have only been studied in
vitro, with relatively few showing applicability in vivo due to specific
challenges for each glucose-sensing strategy. For example, PBA
and its derivatives are known for their reversible interaction with
polyol molecules, such as glucose (21), but an efficient interaction
between glucose and PBA, with a subsequent structural change in
the matrix, usually requires a more basic pH than is present in the
physiological environment. The safety and toxicity of PBA conju-
gates also remain to be established. Con A is the most commonly
used GBP for insulin delivery, generally based on its multiple
binding sites and competitive interaction with glucose and dextran
matrix (22). However, the verified in vivo toxicity and instability of
Con A limit its clinical applications (23). GOx is an enzyme that can
convert glucose to gluconic acid in the presence of oxygen (10):
Glucose+O2 +H2O !GOX Gluconic Acid+H2O2.
Glucose-responsive systems using GOx are always integrated with
pH-sensitive materials, which are either protonated or degraded
with a local decrease of pH, promoted by increasing glucose
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concentration. However, such pH decrease-dependent methods
are often compromised by slow responsiveness, especially in a
buffered physiological environment (8). Taken together, chal-
lenges remain to demonstrate a method that would combine
(i) fast responsiveness with pharmacokinetics similar to normal
pancreatic activity, (ii) ease of administration, and (iii) biocom-
patibility without long-term side effects (3).
Here, we report a novel glucose-responsive insulin delivery
device based on microneedle (MN)-array patches integrated with
hypoxia-sensitive hyaluronic acid (HS-HA) vesicles containing
insulin and GOx. Instead of using enzymatically induced pH
changes (3, 8), for the first time to our knowledge, we have taken
advantage of the local generation of hypoxia due to the con-
sumption of oxygen in the enzymatic reaction as a trigger for
rapid insulin release in response to hyperglycemia. To achieve
hypoxia-responsive transduction, 2-nitroimidazole (NI), a hy-
drophobic component that has often been applied in cancer
imaging due to its high sensitivity to the hypoxic condition in
tumor sites, was used (24, 25). NI can be converted to hydro-
philic 2-aminoimidazoles under a hypoxic environment via a
single-electron reduction catalyzed by a series of nitroreductases
coupled to bioreducing agents, such as NADPH, a plentiful co-
enzyme in tissues (24–27). We conjugated amine-functionalized
NI with HA (molecular mass of 300 kDa), which is well known to
have excellent biocompatibility and biodegradability (28–30). As
shown in Fig. 1A, through self-assembly, the amphiphilic HS-HA
can readily form nanoscale glucose-responsive vesicles (GRVs)
encapsulating both recombinant human insulin and GOx in an
aqueous solution. In the presence of a high blood glucose level,
the dissolved oxygen can be rapidly consumed due to the glucose
oxidation catalyzed by GOx (3, 10), which produced a local
hypoxic environment. NI groups on the HS-HA were then re-
duced into hydrophilic 2-aminoimidazoles under bioreductive
conditions, which resulted in the dissociation of GRVs and
subsequent release of insulin.
To realize ease of administration, we further loaded the GRVs
into a MN-array patch for painless (31–34) insulin delivery (Fig.
1B). The matrix of MNs was made from cross-linked HA to
improve the stiffness of MNs and restrict the loss of GRVs from
needles. With transcutaneous administration, the GRVs loaded
in MNs disassembled when exposed to high interstitial fluid
glucose in vascular and lymph capillary networks (35), thereby
promoting the release of insulin, which was then taken up quickly
through the regional lymph and capillary vessels (36). We dem-
onstrated that this “smart insulin patch” with a novel glucose-
responsive mechanism displayed rapid responsiveness for glucose
regulation and reliable avoidance of hypoglycemia in a mouse
model of type 1 diabetes.
Results
Synthesis and Characterization of GRVs.GRVs were formed by self-
assembly of HS-HA, encapsulating recombinant human insulin
and GOx in the core. The HS-HA was obtained via the formation
of an amide bond with amine-functionalized NI in three steps
(Fig. S1). The incorporation of hydrophobic NI groups renders
the derived HA amphiphilic, enabling the formation of GRVs in
the aqueous solution (37, 38). Moreover, NI provides an hypoxia-
sensitive element, which is expected to be bioreduced under
hypoxic conditions (24, 27). The reduced product with amine
groups is water-soluble, leading to disassembly of GRVs. As pre-
sented in the transmission electron microscopy (TEM) image (Fig.
2A), the resulting GRVs had a spherical shape with a mono-
disperse size. The average diameter of GRVs was determined as
118 nm by dynamic light scattering (DLS) (Fig. 2B), which is
consistent with observation by TEM. The zeta-potential of GRVs
was measured as −34.7 ± 0.4 mV due to the residual carboxyl of
HA. The fluorescence image of GRVs with FITC-labeled insulin
further verified successful encapsulation of insulin (Fig. 2D). The
insulin loading capacity of GRVs was determined as 8.7% (wt/wt).
Importantly, the obtained GRVs were highly stable, and no sig-
nificant precipitation was observed at 4 °C for 1 mo.
In Vitro Glucose-Responsive Insulin Release of GRVs. To examine
the glucose-responsive disassembly of GRVs, vesicles were in-
cubated with PBS buffer [137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4 (pH 7.4)] containing different con-
centrations of glucose, including a typical hyperglycemic level
(400 mg/dL), a normoglycemic level (100 mg/dL), and a control
level (0 mg/dL). The oxygen consumption, caused by the oxida-
tion of glucose catalyzed by GOx, was measured using an oxygen-
sensitive phosphorescent molecular probe (39, 40). As presented
in Fig. 2F, the sample exposed to the hyperglycemic solution had
a lower oxygen concentration compared with the other two
control samples. Of note, equilibrium was achieved in 10 min,
suggesting that the oxygen consumption rate reached equilibrium
with the dissolution rate at this time. The recorded pH value of
incubating solutions with 400 mg/dL glucose solution decreased
steadily over time (Fig. S2), further substantiating the conversion
of glucose to gluconic acid catalyzed by GOx. In this hypoxic
environment, the nitro groups of the HS-HA were effectively
reduced by electrons from NADPH catalyzed by the reductase.
The residual concentration of NI was monitored in real time by
Fig. 1. Schematic of the glucose-responsive insulin delivery system using hypoxia-sensitive vesicle-loading MN-array patches. (A) Formation and mechanism
of GRVs composed of HS-HA. (B) Schematic of the GRV-containing MN-array patch (smart insulin patch) for in vivo insulin delivery triggered by a hyper-
glycemic state to release more insulin.

















measuring the UV-visible (UV-Vis) absorbance intensity of the
characteristic peak of NI at A330 (41). As shown in Fig. 2G, the
corresponding absorbance intensity of GRVs incubated with 400
mg/dL glucose solution gradually decreased over time, suggest-
ing the replacement of hydrophobic NI groups with amine
groups. In sharp contrast, a much slower decline of absorbance
intensity was observed in the samples associated with 100 mg/dL
glucose solution, and no decrease was observed in the control
sample without glucose. Furthermore, the corresponding evolu-
tion of conformation and size changes were clearly observed
through TEM imaging and DLS (Fig. 2 A and C). To validate the
release of insulin from the disassembled GRVs further, insulin
conjugated with FITC was encapsulated into GRVs. As demon-
strated in Fig. 2E, the fluorescence signal was more homoge-
neously distributed after exposure of the GRV suspension to
glucose for 1 h, while the original GRV suspension showed a large
amount of cluster signal, verifying the release of FITC-insulin.
A remarkably rapid insulin release profile was achieved from
the sample with a typical hyperglycemic level of 400 mg/dL
glucose due to the dissociation of GRVs, whereas only a small
amount of insulin was released from the GRVs in PBS solution
with none or a relatively normal level of 100 mg/dL glucose (Fig.
3A). To validate if the insulin release speed directly corresponds
to the reduction of NI groups as a result of oxygen level rather
than decreased pH level, the insulin release kinetics in pH 4.0
solution were investigated. The result showed that there was
insignificant insulin release of the sample incubated in a pH 4.0
solution, confirming the GRVs were stable under an acidic
condition (Fig. S3). In addition, an alterable kinetic release
profile of insulin was observed by varying glucose concentration
(Fig. 3B). A maximum of a 6.6-fold difference in insulin release
rate was achieved in 20 min when the glucose concentration was
changed from 100 to 400 mg/dL. In contrast, GRVs containing
one-half the amount of GOx showed a slower release rate due to
a relatively slower oxygen consumption rate, suggesting that the
insulin release rate can be tuned by varying the encapsulation
dose of enzyme. Moreover, the insulin release profile of GRVs
presented a pulsatile pattern when alternatively exposed between
a normal and hyperglycemic state every 20 min for several cycles
(Fig. 3C). Importantly, the GRVs responded to changes in glu-
cose concentrations rapidly compared with existing synthetic
glucose-responsive systems (3, 8). For example, the hypoxia-
sensitive GRVs displayed a significantly faster response rate to
hyperglycemic levels compared with pH-sensitive–based glucose-
responsive formulations previously reported in parallel (19) with
the same amount of enzymes (Fig. S4). This finding can be at-
tributed to the faster attainment of the “structural transforma-
tion point” for dissociation of the formulation triggered by the
local hypoxic microenvironment than by the local acidic environ-
ment. Collectively, the results discussed above substantiated that
the disassembly of GRVs and the release of insulin underwent a
glucose-mediated and hypoxia-dependent process. Additionally,
the CD spectrum showed that the secondary conformational
structure of released insulin from GRVs (0.1 mg/mL) did not
change compared to that of the native insulin (Fig. 3D).
Fabrication and Characterization of GRV-Loaded MN-Array Patch. To
achieve convenient administration, we next fabricated an MN-
array (32, 34, 42) patch containing GRVs as a painless and dis-
posable modality (32) for administering insulin. Briefly, the
GRVs were first loaded in tips of a silicone mold for MNs
by centrifugation, followed by drop-wise addition of a solution
containing methacrylated HA, the cross-linker N,N’-methyl-
enebisacrylamide, and a photoinitiator (Fig. 4A). Under UV ir-
radiation, the HA matrix was photo–cross-linked to enhance the
stiffness of MNs and entrap the GRVs in the needles. The
resulting MNs were arranged in an 11 × 11 array with an area of
6 × 6 mm and backed for stability during handling using medical
tape (Fig. 4B). Each needle was conical, with a base radius of
150 μm, a height of 600 μm, and a tip radius of ∼10 μm (Fig. 4C).
Fig. 4D shows the fluorescence image of a representative MN
that contains FITC-insulin–loaded GRVs, indicating that GRVs
were evenly distributed inside the needle tips. Measurement of
mechanical strength using a tensile compression machine in-
dicated a failure force for cross-linked MNs of 0.06 N per needle,
compared with only 0.02 N per needle for non–cross-linked MNs
(Fig. 4E). The stiffness of cross-linked MNs provided sufficient
strength to facilitate skin insertion without breaking (42).
To investigate whether GRVs encapsulated in the MN main-
tained their glucose-responsive capability after MN fabrication,
the tips of the needles containing GRVs were immersed into
PBS buffer containing different concentrations of glucose. As
shown in Fig. S5, there was negligible difference between GRVs
in the MNs and GRVs free in suspension (Fig. 3A).
Fig. 2. Characterization of GRVs. (A) TEM images of GRV-encapsulated insulin and enzyme (i) preincubation or postincubation with 400mg/dL glucose for (ii) 20 min,
(iii) 1 h, and (iv) 24 h. (Scale bars: 200 nm.) Size distribution of GRVs preincubation (B) and postincubation (C) with 400 mg/dL glucose for 24 h. Fluorescence 2.5D
images of FITC-insulin–loaded GRV solution preincubation (D) and postincubation (E) in 400 mg/dL glucose solution for 1 h at 37 °C. (F) Phosphorescence lifetime
profile over time for the GRVs incubated with different glucose concentration solutions containing an oxygen concentration molecule probe. (G) Monitoring of UV
absorbance intensity of GRVs at A330 over time in different glucose concentrations at 37 °C. Error bars indicate SD (n = 3). a.u., arbitrary unit.
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In Vivo Studies of the MNs for Type 1 Diabetes Treatment. To assess
the in vivo efficacy of the MN-array patches for diabetes treat-
ment, the streptozotocin-induced type 1 diabetic mice were
grouped and transcutaneously exposed to different samples
(Fig. 5A, Top Left), including the blank MNs containing only
cross-linked HA, MNs loaded with human recombinant insulin,
MNs loaded with GRVs containing both insulin and enzyme
[GRV(E + I)], MNs loaded with GRVs containing insulin and
one-half dose of enzyme [GRV(1/2E + I)], or MNs loaded with
GRVs containing insulin only [GRV(I)]. The insulin dose ap-
plied for each mouse was 10 mg/kg. The MN-array patch pene-
trated the dorsum skin of the mouse effectively, as evidenced by
the trypan blue staining (Fig. 5A, Top Right) and H&E staining
(Fig. 5A, Bottom). The microchannels on the skin created by the
MN-array patch rapidly recovered within 6 h postadministration
(Fig. S6). The blood glucose of treated mice in each group was
monitored over time. As shown in Fig. 5B, the blood glucose in
mice treated with GRV(E + I)-loaded MNs quickly declined to
nearly 200 mg/dL within 0.5 h and maintained a normoglycemic
state (<200 mg/dL) for up to 4 h before gradually increasing. We
attributed this fast response rate to the fast generation of the
local hypoxic microenvironment that quickly activated the dis-
sociation of GRVs under a bioreductive condition; the relatively
low diffusion rate of oxygen in vivo compared with hydrogen ions
may facilitate this process further (43–45). When the enzyme
dose in the MNs was reduced from 1 to 0.5 mg/kg, the blood
glucose levels decreased to around 350 mg/dL within 0.5 h, and
steadily increased afterward. In the absence of the enzyme, the
glucose levels did not show a noticeable decline, suggesting that
the GRVs were highly stable in vivo. Correspondingly, mice
administered GRV(E + I)-loaded MNs presented a consistently
higher plasma insulin concentration for at least 24 h than those
mice treated with GRV(1/2E + I)- and GRV(I)-loaded MNs, as
quantified by ELISA (Fig. 5C). The SEM image of GRV(E + I)-
loaded MNs inserted into skin showed collapse with shortened
tips after use (Fig. 5D), further confirming that the loaded GRVs
disassembled under a hypoxic condition.
Next, a glucose tolerance test was conducted at 1 h after
administration of the MNs. The control healthy mice exhibited
a quick increase in blood glucose level upon an i.p. glucose
injection, followed by a gradual decrease to normoglycemia (Fig.
5E). The diabetic mice treated with GRV(E + I)-loaded MNs
showed a delayed increase in blood glucose after glucose in-
jection, and then a rapid decline to a normal state within 30 min.
However, the glucose of the mice administered insulin-loaded
MNs did not decline in 120 min. The area under the curve was
calculated between 0 and 120 min to measure the MN re-
sponsiveness. As shown, GRV(E + I)-loaded MNs had sig-
nificantly faster responsivity toward the glucose challenge
(Fig. 5F).
To assess the in vivo glucose control capability of MN further,
the series administration with MNs was performed. The glucose
level of mice treated with GRV(E + I)-loaded MNs (dose of
5 mg/kg insulin for each mouse) quickly decreased to around
200 mg/dL within 1 h (Fig. 5G). However, glucose did not further
decrease to a hypoglycemic level upon application of another
dose of GRV(E + I)-loaded MNs (dose 5 mg/kg insulin for each
mouse) and maintained a normoglycemic concentration around
200 mg/dL for another 3 h. In contrast, the mice administered
GRV(I)-loaded MNs (dose of 5 mg/kg insulin for each mouse)
or those mice without additional administration showed a
rapid increase in glucose to a hyperglycemic state in 3 h. In-
sulin-loaded MNs were subsequently administered to another
group of mice, and their blood glucose continued to decrease,
leading to a risk of hypoglycemia. The study on the healthy
mice further indicated there is little insulin leak in GRV-
loaded MNs and the risk of hypoglycemia is reduced com-
pared with the insulin-loaded MNs (Fig. 5H). The corre-
sponding hypoglycemia index (defined as the fall in glucose
from the initial reading to the nadir divided by the time over
which this fall was reached) was calculated to measure
quantitatively the extent to which insulin elicited hypoglyce-
mia. GRV-loaded MNs showed a remarkably reduced hypo-
glycemic index compared with insulin-loaded MNs when
administered in a normoglycemic state (Fig. 5I). Moreover,
regarding biocompatibility of the device, HA is found
throughout the human body and the bare GRVs did not show
significant toxicity at various concentrations studied (Fig. S7).
Additionally, there was no significant inflammation observed
in the region 2 d postadministration of GRV(E + I)-loaded
MNs (Fig. S8).
Discussion
Current GOx-based glucose-responsive insulin delivery sys-
tems mainly use matrices consisting of pH-sensitive materials,
which release insulin by either protonation or degradation due to
Fig. 3. In vitro glucose-responsive release of insulin from GRVs. (A) In vitro
accumulated insulin release from the GRVs in several glucose concentrations at
37 °C. *P < 0.05 for GRVs in 400 mg/dL glucose solution compared with GRVs in
100 or 0 mg/dL glucose solution. (B) Self-regulated profiles of the GRVs and GRVs
containing one-half the amount of GOx present the rate of insulin release as a
function of glucose concentration. *P < 0.05 for GRV(E + I) compared with GRV
(1/2E + I). (C) Pulsatile release profile of GRVs presents the rate of insulin release
as a function of glucose concentration (100mg/dL and 400mg/dL). (D) CD spectra
of native insulin solution and insulin released from the GRVs incubated with
400 mg/dL glucose. Deg, degree. Error bars indicate SD (n = 3).
Fig. 4. Characterization of GRV-loaded MN-array patches. (A) Schematic of
the fabrication process of GRV-loaded MN-array patches from a silicone
mold. (B) Photograph of the smart insulin patch with an MN array. (Scale bar:
1 cm.) (C) Fluorescence microscopy image of MN-loaded GRVs with FITC-
labeled insulin. (Inset) Zoomed-in image of MN. (Scale bars: 200 μm.) (D) SEM
image of MN array. (Scale bar: 200 μm.) (E) Mechanical behaviors of the non–
cross-linked and cross-linked GRV-loaded MNs.

















enzymatic generation of gluconic acid. However, their effectiveness
is limited by a slow response upon blood glucose changes, especially
under a buffered physiological environment. This report demon-
strates the first enzyme-based glucose-responsive insulin delivery
strategy, to our knowledge, using sensitivity to hypoxia rather than
pH variance. A local hypoxic microenvironment could be rapidly
generated in PBS buffer solution due to the enzymatic consumption
of oxygen, as evidenced by an oxygen-sensitive phosphorescent
probe. Subsequently, the hydrophobic side-chains of HS-HA were
reduced into hydrophilic chains, resulting in disassembly of GRVs,
subsequently releasing insulin. The obvious change in morphology
could be observed by TEM 20 min postincubation with PBS buffer
containing 400 mg/dL glucose. The in vitro insulin release profile of
GRVs indicated a remarkably faster release rate compared with the
pH-sensitive–based formulations previously reported (19). In ad-
dition, the insulin release kinetics can be adjusted by varying
the enzyme dose both in vitro and in vivo, further implying that
the release of insulin undergoes a glucose-mediated and hypoxia-
dependent process.
Furthermore, the GRVs were integrated into an HA-based
MN-array patch for convenient, painless, and continuous ad-
ministration of insulin. The cross-linked HA matrix not only
Fig. 5. In vivo studies of the MN-array patches for type 1 diabetes treatment. (A) Mouse dorsum and relevant skin (the area within the red dashed line)
transcutaneously treated with an MN-array patch (Top Left), with the image of the trypan blue staining showing MN-array patch penetration of mouse skin
(Top Right). (Scale bar: 500 μm.) (Bottom) H&E-stained section of mouse skin penetrated by one MN-array patch. The skin muscle and fat tissue regions are
indicated by M and F, respectively. The region where MN-array patch insertion took place is indicated by the blue dashed line. (Scale bar: 100 μm.) In vivo
studies of the MN-array patches for type 1 diabetes treatment: blood glucose levels (B) and plasma human insulin concentrations (C ) in streptozotocin
(STZ)-induced diabetic mice after treatment with blank MNs containing only cross-linked HA, MNs loaded with human recombinant insulin, MNs loaded
with GRV(E + I), MNs loaded with GRV(1/2E + I), or MNs loaded with GRV(I). *P < 0.05 for administration with GRV(E + I)-loaded MNs compared with
GRV(1/2E + I)-loaded MNs or GRV(I)-loaded MNs. (D) SEM image of GRV(E + I)-loaded MN after insertion for 4 h. (Scale bar: 200 μm.) (E ) In vivo glucose
tolerance test toward diabetic mice 1 h postadministration of GRV(E + I)-loaded MNs or insulin-loaded MNs in comparison to the healthy control mice.
(F) Responsiveness was calculated based on the area under the curve (AUC) in 120 min, with the baseline set at the 0-min blood glucose reading. (G) Blood glucose
changes of mice treated with additional administration of the MN-array patch 1 h postadministration of GRV(E + I)-loaded MNs. *P < 0.05 for additional ad-
ministration with GRV(E + I)-loadedMNs compared with no additional administration. (H) Blood glucose changes of healthy mice administered anMN-array patch
over time. (I) Quantification of the hypoglycemia index, which was calculated from the difference between the initial and nadir blood glucose readings divided by
the time at which nadir was reached. *P < 0.05 for administration with GRV(E + I)-loaded MNs compared with insulin-loaded MNs. The black arrows indicate the
administration points. Error bars indicate SD (n = 5).
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helped to improve mechanical strength and skin penetration
capability but also restricted the loss of GRVs to avoid burst
release. Additionally, the framework of both needle patches and
vesicles was made from HA, which is highly biocompatible. The
GRV(E + I)-loaded MNs exhibited excellent regulation of glu-
cose into a normal range with fast responsiveness. Furthermore,
in addition to the highly sensitive vesicles, the rapid uptake by
the lymphatics through transcutaneous administration may con-
tribute to the fast responsivity. The in vivo glucose tolerance test
demonstrated not only that GRV-loaded MNs were responsive
to glucose challenge but that they could also efficiently minimize
the risk of hypoglycemia. In addition, the results of serial ad-
ministration with MNs showed that it could precisely control
glucose in a normal range for prolonged periods. Also consid-
ering that mice have reduced sensitivity to the human insulin
used in this study, the real dose for potential human use will be
significantly lower. This smart insulin patch with its novel trigger
mechanism offers a clinical opportunity for closed-loop delivery
of insulin in a fast glucose-responsive, pain-free, and safe man-
ner. It will also guide the development of a useful drug delivery
platform for treating other diseases using artificial vesicles, the
behaviors of which can be “intelligently” activated and self-reg-
ulated by the variation of physiological signals.
Methods
Materials. All chemicals were purchased from Sigma–Aldrich unless otherwise
specified and were used as received. Sodium HA (molecular mass of 300 kDa)
was purchased from Freda Biochem Co., Ltd.. Human recombinant insulin
(27.5 IU/mg of Zn salt) was purchased from Life Technology.
Preparation of GRVs. GRVs were prepared by self-assembly in aqueous so-
lution. Briefly, 20 mg of amphiphilic HS-HA was dissolved in water/methanol
(2:1 vol/vol), followed by addition of 10 mg of human insulin and 1.0 mg of
GOx. The emulsion was stirred at 4 °C for 2 h. Then, the methanol was re-
moved by dialysis against deionized water for 1 d. The pH value of the
resulting GRV suspension was adjusted to 5.3 (the pI of insulin) to remove
the unloaded insulin by centrifugation at 6,200 × g for 10 min and further
filtered by a centrifugal filter (100,000 Da molecular mass cutoff, Millipore)
at pH 7.4. The final GRV suspension was stored at 4 °C for later study. The
insulin loading capacity of GRVs was determined by measuring the loaded
insulin content using a Coomassie Plus protein assay. The zeta-potential and
size distribution were measured on the Zetasizer (Nano ZS; Malvern). The
TEM images of GRVs were obtained on a JEOL 2000FX TEM instrument.
The animal study protocol was approved by the Institutional Animal Care
and Use Committee at North Carolina State University and the University of
North Carolina at Chapel Hill.
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